Yahoo! Finance: Top Stories

H.C. Wainwright Reiterates Buy Rating on Immix Biopharma (IMMX) Following Promising Interim Results from NXC-201 Trial

Jun 7, 2025 - 03:20
 0
H.C. Wainwright Reiterates Buy Rating on Immix Biopharma (IMMX) Following Promising Interim Results from NXC-201 Trial
Read More

Tags:

Previous Article

BofA Reiterates Buy Rating on Asana (ASAN), Lowers PT to $21

Next Article

Jefferies Maintains Buy Rating on Rhythm Pharmaceuticals (RYTM), Sets $80 Price ...

Related Posts

DAT acquires Outgo, enters race to become dominant freight exchange platform

DAT acquires Outgo, enters race to become dominant frei...

May 16, 2025  0

Tesla Stock Is Falling. Is It a ‘Sell the News’ Month?

Tesla Stock Is Falling. Is It a ‘Sell the News’ Month?

Jun 2, 2025  0

Target stock tumbles again as customer backlash over its DEI rollback takes a bite out of sales

Target stock tumbles again as customer backlash over it...

May 22, 2025  0